Astellas Pharma said on January 20 that it has been notified by the US FDA of the lifting of the clinical hold that had been placed on a PI/II trial evaluating the safety and tolerability of its gene therapy AT845…
To read the full story
Related Article
- Astellas Presents Update on PI/II Study of AT845 for Late-Onset Pompe Disease
February 27, 2023
- Astellas to Test Selecta’s IgG Protease with Pompe Gene Therapy
January 11, 2023
- Astellas’ Pompe Gene Therapy Trial Hit with FDA Clinical Hold
June 28, 2022
BUSINESS
- Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
- Otsuka’s Astex Inks Breast Cancer R&D Pact with Genentech
July 7, 2026
- Ribomic, Fujifilm to Join Forces on LNP CDMO Services
July 7, 2026
- Toray Unveils Next-Generation Opioid Painkiller Candidate
July 7, 2026
- Keytruda’s No. 1 Streak Reaches 33 Months: Encise
July 7, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





